Latest & greatest articles for Intrauterine Growth Retardation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on Intrauterine Growth Retardation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on Intrauterine Growth Retardation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for Intrauterine Growth Retardation

1. IGF-I receptor mutations resulting in intrauterine and postnatal growth retardation. (PubMed)

IGF-I receptor mutations resulting in intrauterine and postnatal growth retardation. Approximately 10 percent of infants with intrauterine growth retardation remain small, and the causes of their growth deficits are often unclear. We postulated that mutations in the gene for the insulin-like growth factor I receptor (IGF-IR) might underlie some cases of prenatal and postnatal growth failure.We screened two groups of children for abnormalities in the IGF-IR gene. In one group of 42 patients (...) with unexplained intrauterine growth retardation and subsequent short stature, we used single-strand conformation polymorphism analysis, followed by direct DNA sequencing of any abnormalities found. A second cohort consisted of 50 children with short stature who had elevated circulating IGF-I concentrations. Complete sequencing of the IGF-IR gene was performed with DNA from nine children. We also studied a control group of 43 children with normal birth weights.In the first cohort, we identified one girl who

2003 NEJM

2. A meta-analysis of low dose aspirin for the prevention of intrauterine growth retardation

A meta-analysis of low dose aspirin for the prevention of intrauterine growth retardation A meta-analysis of low dose aspirin for the prevention of intrauterine growth retardation A meta-analysis of low dose aspirin for the prevention of intrauterine growth retardation Leitich H, Egarter C, Husslein P, Kaider A, Schemper M Authors' objectives To determine more precisely the effect of prophylactic low-dose aspirin on intra-uterine growth retardation and perinatal mortality. Searching Eighteen (...) of the review for practice and research Diagnostic studies are required to determine which women are at the greatest risk from intra-uterine growth reduction and pre-eclampsia and are, therefore, the most likely to be helped by aspirin. Bibliographic details Leitich H, Egarter C, Husslein P, Kaider A, Schemper M. A meta-analysis of low dose aspirin for the prevention of intrauterine growth retardation. British Journal of Obstetrics and Gynaecology 1997; 104(4): 450-459 PubMedID Indexing Status Subject

1997 DARE.

3. Low-dose aspirin in prevention and treatment of intrauterine growth retardation and pregnancy-induced hypertension. Italian study of aspirin in pregnancy. (PubMed)

Low-dose aspirin in prevention and treatment of intrauterine growth retardation and pregnancy-induced hypertension. Italian study of aspirin in pregnancy. Meta-analysis of data from several controlled trials has shown that low-dose aspirin reduces the risk of pregnancy-induced hypertension (PIH) and intrauterine growth retardation (IUGR) in women at high risk of these disorders. We have assessed the efficacy of low-dose aspirin in women judged to be at moderate risk. Women were included

1993 Lancet Controlled trial quality: uncertain

4. [Prevention of intrauterine growth retardation and pre-eclampsia by small doses of aspirin. Results of the french multicenter trial EPREDA and comparison with data in the literature; value of uterine Doppler]. (PubMed)

[Prevention of intrauterine growth retardation and pre-eclampsia by small doses of aspirin. Results of the french multicenter trial EPREDA and comparison with data in the literature; value of uterine Doppler]. 1351078 1992 07 16 2018 11 30 0368-2315 21 3 1992 Journal de gynecologie, obstetrique et biologie de la reproduction J Gynecol Obstet Biol Reprod (Paris) [Prevention of intrauterine growth retardation and pre-eclampsia by small doses of aspirin. Results of the french multicenter trial (...) Biol Reprod (Paris) 0322206 0150-9918 64ALC7F90C Dipyridamole R16CO5Y76E Aspirin IM Aspirin administration & dosage therapeutic use Dipyridamole administration & dosage therapeutic use Double-Blind Method Drug Therapy, Combination Female Fetal Growth Retardation diagnostic imaging drug therapy prevention & control Humans Pre-Eclampsia diagnostic imaging drug therapy prevention & control Pregnancy Prospective Studies Ultrasonography, Prenatal standards 1992 1 1 1992 1 1 0 1 1992 1 1 0 0 ppublish

1992 Journal de gynecologie, obstetrique et biologie de la reproduction Controlled trial quality: uncertain